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Major depressive disorder (MDD) is the foremost cause of global disability, being responsible for enormous 
personal, societal, and economical costs. Importantly, existing pharmacological treatments for MDD are partially 
or totally ineffective in a large segment of patients. As such, the search for novel antidepressant drug targets, 
anchored on a clear understanding of the etiological and pathophysiological mechanisms underpinning MDD, 
becomes of the utmost importance. 
The adenosinergic system, a highly conserved neuromodulatory system, appears as a promising novel target, 
given both its regulatory actions over many MDD-affected systems and processes. With this goal in mind, we 
herein review the evidence concerning the role of adenosine as a potential player in pathophysiology and 
treatment of MDD, combining data from both human and animal studies. 
Altogether, evidence supports the assertions that the adenosinergic system is altered in both MDD patients and 
animal models, and that drugs targeting this system have considerable potential as putative antidepressants. 
Furthermore, evidence also suggests that modifications in adenosine signaling may have a key role in the effects 
of several pharmacological and non-pharmacological antidepressant treatments with demonstrated efficacy, such 
as electroconvulsive shock, sleep deprivation, and deep brain stimulation. Lastly, it becomes clear from the 
available literature that there is yet much to study regarding the role of the adenosinergic system in the path-
ophysiology and treatment of MDD, and we suggest several avenues of research that are likely to prove fruitful.   
1. Introduction 
Major Depressive Disorder (MDD) is a debilitating condition, 
affecting 246–286 million people worldwide [1], characterized by 
persistently depressed mood, inability to feel pleasure (anhedonia), 
motivational deficits, increased anxiety, somatic symptoms, cognitive 
impairments, sleep dysfunction, as well as suicidal thoughts and/or at-
tempts [2,3]. The personal, societal, and economic burden of MDD is 
difficult to overstate. Indeed, MDD is the single greatest cause of global 
disability [4], representing a major burden upon public healthcare 
systems, and on the global economy at large. This impact is even greater 
when taking into account the fact that MDD is widely recognized major 
risk factor for other disabling conditions, such as substance abuse dis-
orders [5], and cardiovascular disease [6]. 
The impact of MDD is largely amplified by the fact that the existing 
treatments, which include psychotherapy [7], pharmacological treat-
ment, and other non-pharmacological biological interventions, such as 
transcranial magnetic stimulation [8] or electroconvulsive therapy 
(ECT) [9], are often partially or totally ineffective. In fact, a 2006 
large-scale research effort found that approximately 30 % of patients do 
not respond to any drug treatment [10]. Furthermore, even when 
effective, the existing antidepressants are often not well tolerated, 
causing a myriad of undesirable and often serious side-effects leading to 
treatment discontinuation [11], and seem to primarily target emotional 
symptoms. MDD-induced cognitive dysfunction has been much less 
targeted, despite its role in patient quality of life [12,13]. 
These problems underline the need of developing novel, effective, 
and safe antidepressant compounds. Unfortunately, research efforts 
have largely failed in this regard, likely due to a combination of factors. 
For one, MDD is characterized by an extremely diverse and complex 
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pathophysiology [3,4,14]. In fact, at the neurobiological level, in addi-
tion to monoaminergic dysfunctions [15], MDD is characterized by 
disruptions in glutamate [16,17], γ-amino-butyric-acid (GABA) [17,18], 
and endocannabinoid signaling [19], altered 
hypothalamic-pituitary-adrenal (HPA) axis activity [20,21], increased 
neuroinflammation [22,23], decreased neuro- and synaptogenesis 
[24–26], diminished brain-derived neurotrophic factor (BDNF) 
signaling [27,28], and impaired synaptic plasticity [29,30], among 
other numerous alterations. Furthermore, the etiology of MDD is not yet 
fully understood, with no individual, or group of, causative factors being 
capable of reliably predicting MDD diagnosis. Nonetheless, it is known 
that multiple factors play a role in the development of this disorder, 
including biological (e.g., genetic predisposition, hormonal imbalance, 
inflammatory or metabolic disease), environmental (e.g., early child-
hood adversity, acute trauma, chronic stress), and personal factors (e.g., 
personality traits, cognitive and coping styles, poor social relationships), 
often interacting with one another [31–36]. On the other hand, invest-
ment in neuropsychopharmaceutical development has continually 
decreased in the past decades [37], in part due to the poor 
investment-to-reward ratio that has characterized this field of drug 
development. Importantly, this has also likely influenced the type of 
drugs that have been developed, with most newly developed antide-
pressants being based upon the widely popular monoaminergic hy-
pothesis of MDD, in essence being small improvements upon the 
commercially successful monoamine reuptake inhibitors. Indeed, in the 
last 10–20 years, less than a handful of compounds with partially or 
entirely monoamine-independent mechanisms of action [38–40] have 
been brought to market. 
One as of yet largely unexplored target for antidepressant drug 
development is the adenosinergic system [41–43], here defined as the 
system that encompasses the enzymes responsible for the synthesis and 
catabolism of adenosine, the nucleoside transporters responsible for 
adenosine transport, and the P1 family of purinergic receptors. The 
inattention to the adenosinergic system as a target for MDD is somewhat 
surprising, considering that this ubiquitous neuromodulatory system has 
a modulatory role over most MDD-implicated dysfunctions. Indeed, the 
adenosinergic system has been demonstrated to have functional in-
teractions with the monoaminergic [44,45], glutamatergic [46], 
GABAergic [47], and endocannabinoid systems [48,49], to modulate 
HPA axis [50] and neuroinflammatory activity [51], to be involved in 
the regulation of neuro- and synaptogenesis [52,53], as well as of BDNF 
signaling [54], and to impact synaptic plasticity [55,56]. Furthermore, 
adenosinergic drugs are already commercially available, and are known 
to be mostly safe. In fact, the most widely used psychoactive substance 
in the world – caffeine – exerts its effects through adenosine receptor 
antagonism [42]. Thus, the adenosinergic system appears as a prime 
target for the development of novel antidepressant drugs. Moreover, 
given its widespread interactions with multiple neurobiological systems 
and processes affected in MDD pathophysiology, understanding how 
changes in the adenosinergic system may cause, and/or be caused by 
depressive states would not only inform additional drug development, 
but also further increase our understanding of the pathophysiology of 
MDD. 
As such, the aim of the present review is to provide a broad overview 
of adenosinergic system in relation to both the pathophysiology and 
treatment of MDD. Specifically, after an initial outline of the key ele-
ments in adenosinergic system, as well as of their distribution and 
functioning under physiological conditions, we will sequentially review 
the evidence regarding how each of those elements is affected in MDD 
conditions, including studies in MDD patients and in rodent models of 
MDD. Furthermore, we will review how manipulations of each of those 
elements of the adenosinergic system impact depressive symptoms and 
associated neurobiological dysfunctions. Lastly, we will provide a crit-
ical appraisal of the overall literature allowing suggestions for future 
research on this subject. 
2. Overview of the adenosinergic system 
Adenosine is one of the most ubiquitous and conserved neuro-
modulators in the central nervous system (CNS). In this section we will 
provide a brief overview of the receptors, transporters, and the enzy-
matic pathways responsible for the synthesis and breakdown of adeno-
sine (see Fig. 1), so as to better contextualize the findings relating each of 
those constituents to the pathophysiology and treatment of MDD. 
2.1. Adenosine synthesis, transport and catabolism 
Extracellular adenosine levels in CNS are regulated by a complex 
machinery comprised of synthetic and degradative enzymes, as well as 
transporters. The relative relevance of each element depends on the cell 
metabolic state and, in the case of neuronal cells, their excitability sta-
tus. Under basal conditions extracellular adenosine concentration is in 
the range of 25–250 nM [57], being sufficient for tonic activation of a 
substantial fraction of adenosine receptors. However, pathological sit-
uations involving abnormally high neuronal and astrocytic activity – 
such as hypoxia, ischemia, and seizures – result in markedly elevated 
extracellular concentrations of adenosine, largely due to an increase in 
the extracellular metabolism of adenine nucleotides to adenosine 
[57–59]. Congruently, many adenosine-mediated effects that are 
observed to a lesser extent under normal conditions (e.g. presynaptic 
inhibition of glutamate release), are greatly augmented during such 
pathological events, representing a neuroprotective mechanism 
[59–61]. 
Adenosine is synthetized both intra- and extracellularly. Intracellular 
adenosine synthesis occurs through the dephosphorylation of 5′-aden-
osine monophosphate (AMP) by the cytosolic enzyme 5′-nucleotidase, or 
through the hydrolysis of S-adenosil-homocysteine (SAH) by the enzyme 
SAH hydrolase. Two soluble 5′-nucleotidases have been identified: an 
inosine monophosphate (IMP)-selective cytosolic 5′-nucleotidase, and 
an AMP-selective cytosolic 5′-nucleotidase. The intracellular concen-
tration of AMP under physiological conditions (0.1− 0.5 mM) is much 
lower than the Km values for AMP cytosolic-5′-nucleotidases 
(1− 14 mM). As such, these enzymes only respond to abnormally high 
concentrations of AMP, which are primarily associated with increased 
metabolic activity. A small variation in adenosine triphosphate (ATP) 
catabolism can induce a large increase in AMP concentration, as the 
intracellular concentration of ATP is about 50 times higher than that of 
AMP [58]. This fact contributes to the proposal that the intracellular 
formation of adenosine from catabolism of cytosolic ATP is a highly 
sensitive signal of increased metabolic rate or metabolic stress [58,62]. 
Another source of adenosine is the transmethylation pathway, where 
adenosine results from SAH hydrolysis by SAH hydrolase (SAHH), which 
simultaneously produces l-homocysteine [63]. SAHH is involved in 
transmethylation mechanisms, since SAH results from transmethylase 
activity upon S-adenosylmethionine (SAM). Furthermore, SAM is a 
methyl donor in cells, and through SAM-dependent methyltransferases 
these methyl groups can be transferred to several types of substrates, 
such as nucleic acid, protein, phospholipids, and monoamine neuro-
transmitters, being deeply involved in epigenetic modifications [63,64]. 
SAH is able to inhibit SAM-dependent transmethylation reactions, 
with this inhibition being limited by the metabolic conversion of SAH to 
adenosine and l-homocysteine [63,64]. 
Brain SAHH expression is highest in the cortex and cerebellum, but 
under non-pathological conditions SAHH has low impact upon neuronal 
excitability [65]. This suggests a minor role for SAHH in the control of 
neuronal cytoplasmic adenosine levels, in contrast to what appears to 
occur in cardiac muscle cells [66]. 
At the extracellular level, adenosine is produced by the conversion of 
released adenine nucleotides (especially ATP) via the ectonucleotidase 
pathway, and of cyclic adenosine monophosphate (cAMP) via the ecto- 
phosphodiesterase pathway. Specifically, ATP released as neurotrans-
mitter, neuromodulator or gliotransmitter, by neurons and/or glial cells, 
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undergoes rapid enzymatic catabolism originating adenosine diphos-
phate (ADP), AMP, and adenosine [67,68]. This catabolic process in-
volves multiple ectonucleotidases such as E-NTPDases (ectonucleoside 
triphosphate diphosphohydrolases) – which include CD39, also known 
as NTPDase 1 or ecto-apyrase – E-NPPs (ectonucleotide pyrophospha-
tase and/or phosphodiesterases), alkaline phosphatases (APs), and 
ecto-5′-nucleotidase (CD73) [69,70]. These enzymes vary in several 
important aspects, most notably their specific substrates and 
end-products, but also in their coupling to the plasma membrane [70]. 
E-NTPDases, which possess transmembranar domains, are 
nucleotide-specific and hydrolyze nucleoside tri- and diphosphates, 
resulting in their respective monophosphates [69,70]. E-NPPs, the vast 
Fig. 1. Schematic representation of the adenosinergic system. Depending on energy requirements, intracellular ATP and adenosine are constantly recycled 
through a series of dephosphorylation and phosphorylation steps, mediated by enzymes such as 5′-nucleotidase (5′-NT), adenosine kinase (ADK), AMP kinase 
(AMPK), and S-adenosil-homocysteine (SAH) hydrolase. Extracellular adenosine is synthetized through the hydrolysis of ATP and ADP. Ecto-nucleotide pyrophos-
phatase/phosphodiesterase (E-NPP) and alkaline phosphatase (AP) hydrolyse ATP to AMP. Ecto-nucleoside triphosphate diphosphydrolase (E-NTDPase/CD39) 
hydrolyses of ATP to ADP and ADP to AMP. AMP is further hydrolyzed by Ecto-5′NT/CD73 promoting the formation of adenosine, which can bind to four adenosine 
receptors. Canonically, activation of adenosine receptors either inhibits (A1R and A3R) or stimulates (A2AR and A2BR) adenylate cyclase activity, and cyclic AMP 
(cAMP) production. Changes in phospholipase C (PLC) activity have been described after A1R and A3R activation, and it has also been shown that A2AR, A2BR and A3R 
can couple to Gq-protein. A1R activation also leads to respective increases and decreases in K+ and Ca2+ conductance, leading to neuronal hyperpolarization. 
Adenosine can be transported through the plasma membrane by two families of nucleoside transporters: the equilibrative nucleoside transporter (ENT) which allows 
bidirectional flux by diffusion, and the concentrative nucleoside transporter (CNT) which uses Na+-coupling to transport adenosine to the intracellular space against 
the concentration gradient. Lastly, adenosine can be irreversibly deaminated into inosine by the adenosine deaminase (ADA), with inosine also being a bioactive 
molecule in brain, through A1R, A2AR and A3R binding. 
Abbreviations: 5′-NT, 5′-nucleotidase; A1R, adenosine A1 receptor; A2AR, adenosine A2A receptor; A2BR, adenosine A2B receptor; A3R, adenosine A3 receptor; ADA, 
adenosine deaminase; ADK, adenosine kinase; ADP, adenosine diphosphate; AMP, adenosine monophosphate AMPK, AMP kinase; ATP, adenosine triphosphate; 
cAMP, cyclic AMP; CNT, concentrative nucleoside transporter; DAG, diacylglycerol; Ecto-5′NT/CD73, Ecto-5′nucleotidase/cluster of differentiation 73; E-NPP, Ecto- 
nucleotide pyrophosphatase/phosphodiesterase; ENT, equilibrative nucleoside transporter; E-NTDPase/CD39, Ecto-nucleoside triphosphate diphosphydrolase/ 
cluster of differentiation 39; IP3, inositol trisphosphate; PIP2, Phosphatidylinositol 4,5-bisphosphate; PKA, protein kinase A; PKC, protein, kinase C; PLC, phos-
pholipase C; SHA, S-adenosil-homocysteine. 
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majority of which also possess transmembrane domains, do not hydro-
lyze AMP, but do hydrolyze nucleoside tri- and diphosphates, in addition 
to also hydrolyzing ADP ribose, dinucleoside polyphosphates, and NAD+
[69,70]. Conversely, both APs and CD73 are bound to the plasma 
membrane through glycosylphosphatidylinositol (GPI) anchoring, being 
primarily involved in local catalysis, and autocrine and paracrine 
signaling. CD73 is a plasma membrane-bound nucleotide-specific 
homodimer, found in both neuronal [71–76] and glial cells [77,78], 
which is primarily responsible for the conversion of extracellular AMP to 
adenosine. APs, on the other hand, are known to hydrolyze nucleoside 
tri-, di- and monophosphates, in addition to also hydrolyzing pyro-
phosphate. Furthermore, in addition to their membrane bound forms, 
soluble CD73 and AP forms do exist, being released by the breakdown of 
GPI anchors, extending the range of action of these enzymes [69,70]. 
As mentioned above, in addition to being synthetized extracellularly, 
adenosine is also synthetized intracellularly, after which it can be 
released to the extracellular space by bidirectional equilibrative nucle-
oside transporters (ENTs). The existing ENT subtypes (ENT1− 4) trans-
port both purine and pyrimidine nucleosides across the plasma 
membrane, in a concentration-gradient dependent manner, thus also 
being involved in the uptake of extracellular adenosine [79,80]. Radi-
oligand binding studies, have reported ENT1 as being most expressed in 
the thalamus and superior colliculus, with reduced hippocampal, 
cortical and cerebellar expression [80–82]. However, it must be noted 
that studies using in situ hybridization have found evidence for marked 
ENT1 mRNA expression in both the hippocampus and the cerebellum of 
rats [83]. ENT2 expression extensively overlaps that of ENT1 [84], with 
mRNA expression being observed in cortical, striatal, thalamic, hippo-
campal, and cerebellar neurons [85]. Unlike ENTs 1 and 2, ENT3 is 
primarily located in the intracellular space, having an especially rele-
vant role in lysosomal functioning [86]. Furthermore, while ENT3 has 
been reported to have CNS expression [87], it is thought to be most 
abundant in the placenta [86]. Lastly, ENT4 mRNA has been found to be 
expressed across the brain of multiple mammalian species [88–91], with 
studies finding ENT4 protein expression in the mouse cerebral cortex, 
hippocampus, basal ganglia, cerebellum, thalamus, and hypothalamus 
[91]. 
Contrastingly, concentrative nucleoside transporters (CNTs) – of 
which three known subtypes exist (CNT1-3) [79,80] – exclusively up-
take extracellular nucleosides, using the force of the transmembrane 
Na+ gradient. The highest CNT1 transcript levels were observed in the 
brain stem and cortex, with intermediate expression in the choroid 
plexus, hypothalamus, hippocampus, and cerebellum. On the other 
hand, CNR2 mRNA was found to be highly expressed in most brain re-
gions [92], but in situ hybridization studies found evidence for greater 
expression in the dentate gyrus of the hippocampus, and the peri-
aqueductal grey, with intermediate expression in the basal ganglia, 
hypothalamus, cortex and cerebellum [92,93]. Furthermore, while some 
evidence suggests that CNT2 may be expressed in astrocytes [94,95], in 
tissue sections it was exclusively found in neuronal cells [93]. Lastly, 
CNT3 expression has been found to be extremely reduced in rat and 
mouse neuronal cells [87], and to be absent, or below the detection 
threshold, in astrocytes [94]. 
The Km values for adenosine vary between transporter subtypes (for 
a review see [79]), with CNTs having higher affinity than ENTs. Within 
ENTs, ENTs 1 and 2 can be considered of high affinity vis a vis ENTs 3 
and 4 [79]. As such, the overall type of translocation processes impli-
cated in adenosine transport (i.e., “concentrative” versus “equili-
brative”) will be contingent upon transporter distribution and affinity. 
Importantly, transport direction varies as a function of ENT activity and 
of the extra- and intracellular concentrations of adenosine, which 
depend on intra- and extracellular purine metabolism. 
Adenosine can be catabolized in both extra- and intracellularly. 
Extracellularly, adenosine is primarily converted to inosine by adeno-
sine deaminase (ADA), though ecto-ADA expression is usually relatively 
low. It is important to note that inosine, once believed to be an inert 
metabolite, is now known to be bioactive, with significant A1R, A2AR 
and A3R interactions in the CNS [96–98]. 
Given the generally reduced expression of ecto-ADA, most extracel-
lular adenosine is taken up by the aforementioned ENTs and CNTs, and 
then catabolized. This occurs mainly through phosphorylation into AMP 
by adenosine kinase (ADK), but also by conversion to inosine by intra-
cellular ADA. Due to ENT activity, both ADK and intracellular ADA 
indirectly regulate extracellular adenosine concentration: studies in the 
hippocampus showed that extracellular adenosine concentrations in-
crease with the inhibition of both ADK [65] and ADA [99,100]. How-
ever, it should be notated that basal adenosine concentrations depend 
not only on the activity of those enzymes, but also on adequate oxygen 
and/or glucose levels [100]. Furthermore, it is possible that the relative 
contribution of each particular enzyme to adenosine level oscillations 
may be cell-specific and, as referred, dependent upon the tissue micro-
environment. Nevertheless, much remains to be determined regarding 
the factors contributing to the regulation of adenosine levels, despite 
attempts having already been made [101]. 
2.2. Adenosine receptors 
Currently, four different adenosine receptors have been identified 
and cloned, namely the A1, A2A, A2B and A3 receptors (A1R, A2AR, A2BR 
and A3R, respectively) [102]. All four receptors are G protein-coupled 
receptors: A1R and A3R are negatively coupled to adenylyl cyclase 
through Gi/o protein α-subunits, whereas A2AR and A2BR are positively 
coupled to adenylyl cyclase through Gs proteins. Changes in the activity 
of phospholipase C activity have been described after A1R [103,104] and 
A3R [105] activation, and it has also been shown that A2AR, A2BR and 
A3R can couple to Gq11 [102]. In the striatum, A2AR are mainly coupled 
to Golf [106], a G-protein abundant in this brain area, that also activates 
adenylyl cyclase [107]. Adenosine receptors also have significantly 
different densities and affinities for adenosine: A1R and A2AR are 
widespread and have high affinity for adenosine, whereas A2BR and A3R, 
which are less expressed and have lower affinity [57,108]. However, it 
must be noted that the affinity of A3R for adenosine is 
species-dependent, being high in humans and low in rodents [109]. 
Adenosine receptors are differentially expressed in different areas of 
CNS. A1R is highly expressed in the cortex, cerebellum, hippocampus, 
and dorsal horn of spinal cord, whereas A2AR is highly expressed in the 
striatum and olfactory bulb, being expressed to a lower extent in other 
brain regions [110], such as the amygdala, hippocampus or prefrontal 
cortex [111–113]. The overall modulatory role of adenosine in the CNS 
is mainly contingent upon on the balance between A1R and A2AR activity 
[59]. Both receptors can be present in the same synapse, with approxi-
mately 80 % of hippocampal nerve terminals expressing both A1R and 
A2AR [114]. Furthermore, in the hippocampus, neuronal A1R and A2AR 
expression is predominantly, but not exclusively, presynaptic [55, 
114–118]. 
A1R are most abundant in neurons, both pre- and postsynaptically 
[115,116,119], but are also expressed in glial cells, such in astrocytes 
[120] and microglia [121]. At the presynaptic level, A1R activation 
decreases the release of several neurotransmitters, including glutamate, 
acetylcholine, serotonin (5-HT) and dopamine (DA), leading to the in-
hibition of synaptic transmission [122,123]. At the postsynaptic level, 
A1R activation is associated with the inhibition of glutamate N-meth-
yl-D-Aspartate receptor (NMDAR) mediated currents [124], inhibition of 
voltage sensitive Ca2+ channels [122], increased K+ conductance [125], 
and disinhibition of inhibitory neurons through a decrease of GABAA 
receptor-mediated tonic inhibition [126]. These actions make it so that 
A1R plays a key role in the regulation of synaptic transmission and 
plasticity, with its activation inhibiting hippocampal long-term poten-
tiation (LTP), [127] and long-term depression (LTD) [128]. 
On the other hand, despite having relatively little hippocampal 
expression [111,129], A2AR are readily activated by extracellularly 
generated adenosine, to facilitate neurotransmitter release [130], and 
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can have significant impact in hippocampal synaptic plasticity. Pre-
synaptically, A2AR stimulation is triggers the release of several neuro-
transmitters, including glutamate [131,132], acetylcholine [133], DA 
[134], 5-HT [135], and GABA [131,136]. In addition, presynaptic A2AR 
play a critical role in supressing cannabinoid type 1 receptor- (CB1R), 
and A1R-mediated inhibition [137,138]. Postsynaptically, A2AR modu-
late the activation of NMDAR [118,139,140], CB1R [141], metabotropic 
glutamate receptor 5 (mGluR5) [142], DA type 2 receptors (D2R) [143]. 
Moreover, insofar postsynaptic A2AR are necessary for the co-activation 
of NMDAR [140], they are required for the maintenance of LTP [144]. 
Additionally, A2AR activity is known the facilitate the effects of BDNF 
upon synaptic transmission and plasticity [144–146]. 
As previously described, there are two major sources of extracellular 
adenosine. On the one hand, under rest or low-frequency stimulation, 
A1R is primarily activated by ENT-released adenosine [147]. On the 
other hand, conditions of increased presynaptic stimulation favor the 
release of ATP, which is then metabolized to adenosine. This pathway 
leads to preferential A2AR activation [130,147]. Thus, adenosine 
induced suppression of neuronal activity, preservation of ATP stores, 
and neuroprotection [148] are mainly attributable to A1R activation, 
while A2AR activation, may exacerbate excitotoxicity in several brain 
areas [149–152]. Importantly, however, despite A2AR being mainly 
associated with pathological situations, these receptors also gate the 
neuroprotective actions of some molecules, such as neurotrophic factors 
[145,146,153]. 
Unlike A1R and A2AR, A2BR has a low level of expression in the brain, 
being primarily expressed in peripheral tissues [154]. Lastly, A3R is 
reported to have intermediate levels of expression in the human cere-
bellum and hippocampus, and low levels in most of the remaining re-
gions [102]. Besides their reduced expression in the brain, A2BR and A3R 
also have low-affinity for adenosine [155]. Nonetheless, these receptors 
might be activated during conditions of hypoxia or ischemia, in which 
extracellular adenosine levels rise [58,156–158]. 
Lastly it must be noted that, in addition to their neuronal expression, 
all four adenosine receptors are detected in astrocytes [159], and have 
been reported to be expressed in microglial cells or microglial cell lines 
[160,161]. 
3. The adenosinergic system in MDD pathophysiology and 
treatment 
3.1. Adenosine synthesis 
The impact of MDD-like conditions on the levels and activity of en-
zymes involved in adenosine synthesis have been investigated in mul-
tiple animal studies. ATPase, ADPase and CD73 activity were assessed in 
synaptosomes derived from the spinal cords of male and female Sprague- 
Dawley rats, that had undergone a chronic restraint stress procedure 
[162]. In this work, the authors found male-specific decreases and in-
creases in ADPase and CD73 activity, respectively, with no changes in 
ATPase activity [162]. Interestingly, in this study no effects were 
observed in females [162], likely due to the effects of estradiol, as evi-
denced by a posterior study in ovariectomized female rats, where 
chronic restraint stress induced a decrease in spinal cord CD73 (but not 
ATPase or ADPase) activity, which was not observed in similarly 
stressed 17β-estradiol-treated animals [163]. 
In another study from these authors, neither ATPase, ADPase, nor 
CD73 activity were observed to be altered in synaptosomes derived from 
the hypothalamus and cortex derived of male Sprague-Dawley rats 
exposed to a similar chronic restraint stress protocol [164]. Moreover, in 
these animals, a decrease in blood serum ADPase activity was observed 
[164]. Furthermore, both 15- and 40-day restraint stress exposures were 
found to induce increased ATPase activity in hippocampal synaptosomes 
obtained from male Sprague-Dawley rats, without affecting ADPase or 
CD73 activity [165]. 
In recent years there has been an increase in the number of studies 
using zebrafish as model organism for the study of depression, and of 
putative treatments for it. This is likely due to the fact that not only do 
zebrafish allow rapid, low-cost, high throughput manipulation and 
testing, but also due to their remarkably high physiological and genetic 
homology to mammals [166,167]. Moreover, zebrafish models have 
been demonstrated to have considerable predictive value, in regards to 
detecting the effects of known antidepressant compounds [166,167]. 
Interestingly, a recent study with zebrafish exposed to an unpredictable 
chronic stress protocol, found no differences in the hydrolysis of either 
ATP, ADP or AMP, suggesting no changes in enzymatic activity [168]. 
However, it should be noted that, despite this lack of changes in the 
activity of hydrolytic enzymes, when ATP metabolism was measured 
directly, a significant increase in ATP-derived adenosine levels was 
observed in the brains of stress-exposed zebrafish [168]. 
A recent study found that chronic social defeat stress (CSDS) expo-
sure resulted in increased hippocampal CD39 expression and activity, as 
well as a marked depressive-like state, as evidenced by increased 
immobility time in the tail suspension (TST) and forced swim tests (FST), 
and decreased sucrose intake in the sucrose preference test (SPT) [169] 
(for a brief overview of the most common behavioral tests used in the 
assessment of depressive- and anxiety-like behaviors see Table 1). 
Furthermore, it was also found that CSDS induces an equally strong 
anxiogenic effect in the elevated plus maze (EPM) and the Open Field 
Test (OFT) [169]. Most notably, these authors found that both phar-
macological and genetic silencing of hippocampal CD39, resulted in a 
partial reversal of CSDS-induced depressive-like behaviors, and associ-
ated molecular alterations, including increased hippocampal neuro-
genesis, spinogenesis, and extracellular ATP level [169]. Congruently, 
administration of the CD39-analog apyrase resulted in CSDS-like in-
creases in depressive-like behaviors [169]. Conversely, in non- 
CSDS-exposed mice, genetic or pharmacologic silencing of hippocampal 
CD39 resulted in antidepressant-like effects, with animals performing 
better than controls [169]. Thus, hippocampal CD39 seems to have a key 
role in the regulation of mood states, and may represent an important 
target for future drug-development. However, these results must be 
considered in light of the fact that CD39 silencing may imply other 
undesirable effects, as evidenced by the fact that CD39-KO mice have 
been reported to be highly seizure-prone [196]. Nonetheless, in agree-
ment with the data of 
Cui et al. [169], CD39-KO mice were reported to show decreased 
anxiety-like behavior in the EPM, without alterations of in the social 
interaction test (SIT), the OFT, or the fear conditioning paradigm [196]. 
On the other hand, the impact of CD73 manipulations was assessed 
in a pair of studies with CD73-KO mice. In the first of these studies, 
CD73-KO mice were found to have wild type (WT)-like performance in 
the EPM, OFT and the light-dark box test (LDBT), as well as in the FST, 
and the fear conditioning paradigm, thus suggesting unaltered 
emotional function [197]. In line with this data, another study reported 
the LDBT and OFT performance of CD73-KO mice to be similar to that of 
controls [198]. Intriguingly, regarding cognitive parameters known to 
be impacted in MDD, it was first reported that neither working memory, 
nor spatial memory and learning were affected in CD73-KO mice [197]. 
However, a subsequent study observed an improvement in working 
memory, assessed in the Spontaneous Alternation Y-Maze, in CD73-KO 
mice [198]. Furthermore, CD73-KO mice evidenced altered social 
behavior, with decreased social dominance, and preference for social 
novelty in the social motivation and social novelty test, despite pre-
senting increased social activity [197]. 
Interestingly, there is some evidence that conventional antidepres-
sants may significantly impact the enzymes involved in adenosine syn-
thesis (see Table 2 for an overview of the effects of classical 
antidepressant treatments upon the adenosinergic system). In the blood 
serum, acute treatment with the tricyclic antidepressant (TCA) 
nortriptyline – but not the selective 5-HT re-uptake inhibitor (SSRI) 
fluoxetine – led to a decrease in ATP hydrolysis, without affecting ADP 
or AMP hydrolysis [199]. Similarly, acute nortriptyline, but not 
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Table 1 
Overview of the most widely used behavioral tests for the assessment of anxiety- and depressive-like behaviors.  
Test Description Construct 
Modelled 
Main Measures Limitations/Biases Key Refs. 
Differential 
Reinforcement of 
Low-rate 72-s (DRL- 
72-s) 
Animals are trained to acquire a stable pattern of 
operant behavior, whereby lever presses are only 




Number of responses (index of 
depressive-like behavior) 
Biased by impairments in 
learning processes; 
[170] 
Number of reinforcers obtained 
(inverse index of depressive-like 
behavior) 
Cumulative inter-response time 
distribution (rightward 
shift = inverse index of 
depressive-like behavior) 
Elevated Plus Maze 
(EPM) 
Animals are placed in the center of an elevated 
maze shapes like a plus – with two open arms and 
two arms enclosed on three sides by high walls – 




Time spent and number of entries 
in the open arms (inverse indexes 
of anxiety-like behavior); 




May not be an adequate 






Animals are conditioned to associate conditioned 
stimuli (cue) with an aversive unconditioned 





Cue-evoked freezing responses 
(index of cued conditioned fear); 




Subsequently animals are exposed to the cue in a 
novel environment (cued fear conditioning), 
and/or to the context where original 
conditioning took place but in the absence of the 
cue itself (contextual fear conditioning). 
(e.g., phobia) 
Context-evoked freezing 
responses (index of contextual of 
conditioned fear); 
Forced Swim Test (FST) 
Animals are placed into a water filled cylinder 
from which they cannot escape for a single 6- 
minute session (mice) or for 2 sessions – lasting 




Time spent in immobility (index 
of depressive-like behavior); 




Time spent climbing (inverse 
index of depressive-like 
behavior); Highly stress inducing; 
Time spent swimming (inverse 
index of depressive-like 
behavior); 
Light-Dark Box Test 
(LDBT) 
Uses an apparatus composed by two chambers – 
one dark, and fully covered, the other open and 
brightly lit – connected by a small passage. 
Animals are placed in the dark chamber and 
allowed to freely explore the entire apparatus for 
a defined period of time. 
Generalized 
anxiety 
Latency to first entry in the light 
chamber (index of anxiety-like 
behavior); Biased by alterations in 
locomotor function; 
[178, 
179] Time spent in the light chamber 
(inverse index of anxiety-like 
behavior); 
Marble Burying Test 
(MBT) 
Animals are placed in a cage with lightly tamped 
bedding, on top of which an array of glass 
marbles has been disposed, and left to explore/ 




Number of marbled buried 
(index of anxiety-like behavior) 





Open Field Test (OFT) 
Animals are placed in an enclosure whose center 
region is brightly lit, and are allowed to freely 
explored for a defined period of time. 
Generalized 
anxiety 
Time spent in a virtually defined 
center zone (inverse index of 
anxiety-like behavior); 




May not be an adequate 
measure of anxiety-like 
behavior; 
Locomotor measures (distance 
travelled, average speed); 
Limited predictive 
validity; 
Shuttle Box Escape 
Animals are first exposed to inescapable shocks 
on one of two compartments in a conditioning 
chamber, with no way to access the other 
compartment. After a defined period of time, 
animals are again placed in the shock-paired 
compartment, with open access to the remaining 




Number of shocks received when 
escape is possible (escape 
failures; index of depressive-like 
behavior); 




188,189] Latency to escape shock (inverse 
index of depressive-like 
behavior); 
Social Interaction Test 
(SIT) 
Animals are placed in the open field with a 
unknown social partner of the same sex, weight 
and age, and allowed to freely explore and 
interact for a defined period of time. 
Social anxiety 
Time spent in active social 
interaction (inverse index of 
anxiety-like behavior); 
Biased by alterations in 








Animals are allowed free access to two bottles – 
one containing water, and the other a low 
concentration sucrose solution – for a defined 
period of time. 
Anhedonia 
Relative sucrose preference 
(inverse index of depressive-like 
behavior); Biased by alterations in 
gustatory perception; 
[192, 
193] Sucrose intake (inverse index of 
depressive-like behavior); 
Tail Suspension Test 
(TST) 
Mice are hung upside down by their tails for a 
defined period of time (typically 6 min), and 
behavior is scored. 
Impaired stress- 
coping 
Time spent in immobility (index 
of depressive-like behavior); 
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fluoxetine, treatment decreased hippocampal and cortical ATP hydro-
lysis, while also increasing ADP hydrolysis in the hippocampus [200]. 
However, chronic treatment with these compounds led to different re-
sults. In blood serum, both fluoxetine and nortriptyline-treatments led to 
a decrease ATP, ADP, and AMP hydrolysis [199]. On the other hand, the 
hippocampus, both compounds decreased ATP hydrolysis, without 
affecting ADP or AMP metabolism [200]. Moreover, in the cortex, 
fluoxetine treatment decreased ATP hydrolysis, while increasing ADP 
and AMP metabolism, whereas nortriptyline increased hydrolysis of 
both ATP, ADP and AMP [200]. However, it should be noted that 
another study found fluoxetine treatment to have no impact upon whole 
brain apyrase mRNA expression [201]. Relatedly, a recent study with 
zebrafish found that pre-treatment with the CD73 inhibitor AMPCP did 
not diminish or increase the antidepressant-like actions of the NMDAR 
antagonist MK-801 [202]. 
Like classical antidepressant compounds, electroconvulsive shock 
(ECS) treatment has also been shown to modulate adenosine synthesis. 
In the short term, 12 h after a single ECS session, blood serum ADP and 
AMP hydrolysis was found to be decreased [203]. On the other hand, 
when similar assessments were performed 7 days after the last of an 
8-session ECS treatment protocol, persistent increases in ATP and ADP 
hydrolysis were observed in both serum and cerebral spinal fluid sam-
ples, suggesting a role for increased adenosine synthesis in the antide-
pressant effects of ECS [203,204]. 
Finally, it must be noted that alterations in the intracellular adeno-
sine precursor SAM, have been shown to translate into alterations in 
methyltransferase activity, resulting in abnormal methylation patterns. 
Importantly, such aberrant methylation patterns have been implicated 
Table 2 
Impact of pharmacological and non-pharmacological antidepressant treatments on adenosine synthesis, transport, catabolism, levels and P1 receptors.   






A1R A2AR A2BR A3R 
DBS – – – ↑hipp A,B – – – – 
ECS/ECT 
↓ Serum ADP/AMP 
hydrolysisA 




↑ Ctx densityC 
↔ Ctx, Hipp, Cbl, Str 
densityA,C 
– – 
↑ Serum & CSF ATP/ADP 
hydrolysisC 
↔ Ctx, Hipp, Cbl densityA ↔ Hipp, Cbl, Str 
densityC  
↔ Ctx, Hipp, Cbl, Str, 
densityC 
↔ Ctx, Hipp, Cbl, 
Str densityA 
MAOI – – – – – – – – 
MRA – – – – – – – – 
NaSSA – – – – – – – – 
NDRI – – – – – – – – 
NMDAR- 
A 
– – – – – – – – 
NRI – – – – – – – – 
RIM-A – – – – – – – – 
SARI – – ↓ ADA activityE – – – – – 
SD – – – ↑BFA ↑ BF densityA,C,F ↓ OT densityC – –      
↑ BF mRNAA ↓ OT mRNAA   
SMS – – – – – – – – 
SNRI – – – – – – – – 
SSRI 
↔ Serum ATP/ADP/AMP 
hydrolysisA 
↑ whole-brain CNT2 
mRNAB 
↑ Serum ADA 
activityC,F 
↑ PlasmaA,C,F – – – – 
↓ Serum ATP/ADP/AMP 
hydrolysisC 
↔ whole-brain ENT1− 3, 
CNT3 mRNAB 
↔ whole-brain ADK 
mRNAB 
↔ Hipp & Ctx ATP/ADP/ 
AMP hydrolysisA 
↓ Hipp ATP hydrolysysC 
↔ Hipp ADP/AMP 
hydrolysisC 
↑ Ctx ADP/AMP hydrolysisC 
↓ Ctx ATP hydrolysisC 
TCA 
↓ Serum ADP hydrolysisA 
↓ activityD ↔ ADA & ADK 
activityD 
– – – – – 
↔ Serum ATP/AMP 
hydrolysisA 
↓ Hipp & Ctx ATP 
hydrolysisA 
↑ Hipp ADP hydrolysisA 
↔ Hipp & Ctx AMP 
hydrolysisA 
↓ Serum ATP/ADP/AMP 
hydrolysisC 
↓ Hipp ATP hydrolysysC 
↔ Hipp ADP/AMP 
hydrolysisC 
↑ CTX ATP/ADP/AMP 
hydrolysisC 
Abbreviations: -, effects not studied; ↔ no effects; ↓ decrease; ↑ increase; A1R, Adenosine A1 receptor; A2AR, Adenosine A2A receptor; A2BR, Adenosine A2B receptor; 
A3R, Adenosine A3 receptor; ADA, adenosine deaminase; ADK, adenosine kinase; ADP, adenosine diphosphate; AMP, adenosine monophosphate; ATP, adenosine 
triphosphate; BF, basal forebrain; Cbl, cerebellum; CNT, concentrative nucleoside transporter; CSF, cerebral spinal fluid; Ctx, Cortex; DBS, deep brain stimulation; ECS/ 
ECT, electroconvulsive shock/therapy; ENT, equilibrative nucleoside transporter; Hipp, hippocampus; MAOI, monoamine oxidase inhibitor; MRA, melatonin receptor 
agonist; NaSSA, noradrenaline and serotonin specific antidepressant; NDRI, noradrenaline and dopamine reuptake inhibitor; NMDAR-A, NMDA receptor antagonist; 
NRI, noradrenaline reuptake inhibitor; OT, olfactory tubercle; RIM-A, reversible inhibitor of monoamine oxidase A; SARI, serotonin antagonist and reuptake inhibitor; 
SD, sleep deprivation; SMS, serotonin modulator and stimulator; SNRI, serotonin and noradrenaline reuptake inhibitor; Str, striatum; TCA, tricyclic antidepressant. 
a, acute administration; b, sub-chronic administration; c, chronic administration; d, cell line study; e, ex-vivo application; f, human MDD patients. 
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in the pathogenesis of multiple neuropsychiatric disorders, including 
MDD [64,205]. 
In sum, evidence appears to largely support the existence of an 
important role for altered adenosine synthesis in the emergence of MDD 
symptoms. Moreover, it seems to be the case that targeting those dys-
functions in adenosine synthesis has a significant beneficial effect over 
symptoms, and thus may hold significant therapeutic potential. 
3.2. Adenosine transport 
Given that sleep disruption and fatigue are common symptoms of 
MDD, and considering the role of adenosine in sleep regulation, a 
possible relationship between adenosinergic dysfunction and MDD- 
associated sleep disruption has been proposed. In line with this, a 
study assessed the association between a number of single nucleotide 
polymorphisms (SNPs) – in the genes coding for ADA, ADK, ENTs, CNTs, 
and CD73 – and MDD diagnosis with or without sleep disturbances, in 
patients of both sexes [206]. While in initial analyses these authors 
found multiple significant associations between specific SNPs and MDD, 
only one survived correction for multiple comparisons [206]. Specif-
ically, a significant female-specific association was found between the 
SLC29A3 rs12256138 SNP and MDD diagnosis, suggesting a possible 
involvement between ENT3 alterations and this disorder [206]. 
The role of nucleoside transport in depressive-like symptoms in ro-
dents has also been studied by both genetic and pharmacological ap-
proaches. Pharmacological studies found that administration of the non- 
specific transporter inhibitor papaverine, led to an anxiolytic-like effect 
in the EPM [207]. Similarly, microinjection of the specific ENT1 
antagonist NBMPR into the amygdala, but not the caudate-putamen, of 
C57BL6 mice, resulted in an anxiolytic-like effect in both the EPM and 
the OFT [208]. Likewise, when male ENT1-KO mice were assessed, a 
significant decrease in anxiety-like behavior was observed in the EPM, 
OFT and LDBT [208,209], but not in the marble burying test (MBT) 
[209]. Moreover, female ENT1-KO mice tested in the OFT and the MBT, 
also evidenced decreased anxiety in those tests [209]. Furthermore, 
when ENT1-KO mice of both sexes were assessed for altered 
depressive-like behaviors in the FST, a significant antidepressant-like 
effect was observed, as evidence by reduced immobility time as 
compared with WT littermates [209]. 
One interesting discrepancy, however, comes from the fact that acute 
administration of the ENT inhibitor NBTI resulted in a dose-dependent 
impairment in shuttle box escape performance, similar to that 
observed after inescapable shock exposure [210], suggesting a prode-
pressant impact of transporter blockade. Moreover, when NBTI was 
combined with a sub-effective shock exposure, a synergistic effect was 
observed [210]. 
A few studies have assessed how adenosine transporters are 
impacted and impact antidepressant treatment. Specifically, 3-day 
fluoxetine treatment led to an increase in whole-brain CNT2 mRNA 
expression, without altering that of ENT1− 3, CNT3, or ADK [201]. 
Furthermore, there is some evidence that the TCA amitriptyline may 
inhibit adenosine transport [211]. Interestingly, while it has been 
demonstrated that a single ECS exposure rapidly (30 min) induces 
marked increases in striatal adenosine uptake, these appear to be 
short-lasting, not being detectable 24 h later [212]. Similarly, repeated 
ECS treatment had no significant effect upon adenosine uptake – in 
either the striatum, the cortex, the hippocampus, or the cerebellum – 
when measurements were performed 24 h after the last session [212]. 
Lastly, recent study with zebrafish found that NBTI co-treatment had 
no impact upon the antidepressant-like action of the NMDAR antagonist 
MK-801 [202], but in contrast, dipyridamole, a non-specific nucleoside 
transport inhibitor, synergistically acted with MK-801, increasing its 
antidepressant-like effects [202]. Accordingly, acute dipyridamole 
administration potentiated the antidepressant-like effect of sub-effective 
zinc chloride doses, in the FST [213]. 
Altogether, the presently available evidence cannot firmly support a 
conclusion regarding the possible involvement of adenosine transporters 
in the pathophysiology of MDD, nor the possible relevance of nucleoside 
transport inhibitors in MDD therapeutics. The differences between acute 
and prolonged administration of nucleoside inhibitors, the short-lasting 
influence of intense neuronal activity upon extracellular levels of 
adenosine, and the different responses to selective and non-selective 
nucleoside inhibitors are indicative of a strong capability of the nucle-
oside transporters to adapt to changes in the extracellular levels of 
adenosine and to drug manipulations. Whether this might explain some 
of the apparent contradictory findings on the role of the transporters on 
depression or the action of antidepressant drugs awaits further studies. It 
is also important to keep in mind that ENTs are bidirectional and 
therefore take up or release adenosine as a function of the relative intra- 
and extracellular concentrations of the nucleoside. As such, ENTs in-
hibitors may lead to either increases or decreases in the extracellular 
concentrations of adenosine as a function of the neuronal activity and 
metabolic state of neuronal cells, including neurons, astrocytes and 
microglia. 
3.3. Adenosine catabolism 
To the best of our knowledge, all the published work regarding the 
association between MDD and altered adenosine catabolism, focused on 
ADA, with results being somewhat contradictory. 
In the blood serum of rats exposed sub-chronic (3-day) restraint 
stress, an increase was observed in ADA activity, which was not 
observed after a single restraint session [214]. Similarly, in a study with 
MDD patients, blood ADA activity was found to be increased in the MDD 
group [215]. Contrastingly, however, a previous in a previous study 
with MDD patients, an association was observed between decreased – 
rather than increased – blood serum ADA activity and MDD diagnosis 
[216]. In line with this, a recent paper using zebrafish exposed to a 
unpredictable chronic stress protocol, found a decrease in the activity of 
brain ecto-ADA activity, but not in that of cytosolic ADA [168]. More-
over, these authors assessed how chronic stress impacted the expression 
of several ADA genes, and found no significant alterations [168]. 
Regarding ADA manipulations, a recent study assessed the impact of 
ADA abolishment on behavioral outcomes [217]. These authors found 
that ADA-KO mice presented increased anxiety-like behaviors in the 
OFT and LDBT [217]. Results in the OFT have, however, to be evaluated 
in light of the fact that these animals also presented clear signs of lo-
comotor hypoactivity [217]. Importantly, enzyme replacement therapy 
had no effect upon these behavioral alterations [217]. 
Interestingly, pharmacological inhibition of ADA has been contra-
dictorily reported to induce both pro- and antidepressant-like effects. 
Specifically, a 1998 study showed that acute intracerebroventricular 
administration of EHNA induced escape deficits – similar to those 
observed after exposure to inescapable shocks – in the shuttle box escape 
paradigm [218]. Furthermore, a sub-active EHNA dose, in combination 
with sub-effective shock exposure, resulted in escape deficits similar to 
those observed by active dose EHNA or effective shock exposure, sug-
gesting a synergistic interaction [218]. Conversely, in a more recent 
study, acute intraperitoneal EHNA administration, resulted in 
dose-dependent decreases in FST immobility time – suggesting an 
antidepressant-like effect – without altering OFT performance [219]. 
The effects of ADK manipulation were assessed in a single study, 
where a transgenic mouse line overexpressing ADK (Adk-tg) was 
assessed for alterations in anxiety-like behaviors, and fear conditioning, 
as well as working-, and reference memory [220]. Performance in the 
EPM was found to be WT-like, suggesting normal anxiety-like behavior 
[220]. On the other hand, in the fear conditioning, Adk-tg mice pre-
sented impaired acquisition and expression of the response to condi-
tioned stimuli [220]. Furthermore, these animals evidenced severe 
deficits in both working and reference memory [220]. 
The effects of antidepressant treatment on the enzymes involved in 
adenosine catabolism were first assessed in 1985 paper, which found 
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that the serotonin antagonist and reuptake inhibitior (SARI) trazodone 
acted as an inhibitor of brain ADA [221]. On the other hand, a subse-
quent in vitro study, where amitriptyline was found to not impact the 
activity of either ADK or ADA [211]. In contrast, two subsequent studies 
have found that in both MDD and panic disorder patients, 8-week SSRI 
treatment was associated with significant increases in blood ADA ac-
tivity [215,222]. Curiously, a recent study found that sub-chronic 
(3-day) fluoxetine administration had no impact upon whole-brain 
ADK mRNA expression [201]. Finally, in zebrafish, acute EHNA pre-
treatment did not significantly alter the antidepressant-like effects of 
MK-801 administration [202]. 
Overall, ADA alterations have been consistently observed to be 
related to depressive and anxious symptomatology, and may represent 
fruitful targets for future development. However, it is important to keep 
in mind that ADA manipulations are likely to have markedly unselective 
and widespread effects, some of which may be undesirable. On the other 
hand, there is a clear dearth of research on the role of ADK in the 
pathophysiology and/or treatment of MDD symptoms, which is sur-
prising given the key role of this enzyme in the regulation of intra- and 
extracellular adenosine levels (see section 2.1), and its relevance as a 
therapeutic target multiple other pathologies [223], including neuro-
psychiatric ones [224]. This is, thus, an area which undoubtedly de-
serves future research. 
3.4. Adenosine levels 
Changes in adenosine synthesis, transport and catabolism, found in 
MDD patients and/or animal models, are likely to impact adenosine 
levels, resulting in the non-selective changes in the activation state of 
adenosine receptors. However, to the best of our knowledge, no pub-
lished work has assessed the possibility that adenosine levels may be 
altered in MDD patients or animal models. Nonetheless, a few studies 
have assessed the impact of manipulations aimed at altering adenosine 
levels. 
Acute intraperitoneal administration of adenosine was reported to 
induce marked increases in FST immobility time, which were prevented 
by co-administration of caffeine, theophylline, and some – albeit not all 
– classical antidepressant compounds [225]. In a subsequent study, 
acute intraperitoneal administration of the non-selective adenosine re-
ceptor agonist NECA, resulted in a dose-dependent impairment of escape 
behavior in the shuttle escape paradigm, similar to that induced by 
inescapable shock [226]. 
However, more recent publications have reported adenosine 
administration to induce markedly different effects than those originally 
reported. Indeed, acute adenosine administration has been consistently 
shown to induce reductions in immobility time in both the FST and the 
TST, without altering locomotor activity [227–232]. Furthermore, this 
effect has been demonstrated to be reliant on a number of interactions 
with other – non-adenosinergic – targets, including the nitric oxi-
de–cGMP pathway [228], the 5-HT type 1A [231] and NMDA [227] 
receptors, K+ channels [230], and the opioid system [229]. One possible 
explanation for the discrepancy of results vis a vis those originally re-
ported, related to the differences adenosine doses used [225]. Specif-
ically, whereas antidepressant effects are observed at doses of 
1− 10 mg/kg [227–232], the report finding a prodepressant effect of 
adenosine, administered a 100 mg/kg dose [225], which is likely to 
induce a strong sedating and/or locomotion impairing effect. Nonethe-
less, it must be noted that in a recent study with rats submitted to 
bilateral olfactory bulbectomy (OBX), 14-day adenosine treatment had 
no effect upon altered FST, OFT or SPT performance [233]. 
The impact of antidepressant drug treatment upon adenosine levels 
has been assessed in a single study, where MDD patients underwent a 40- 
day treatment with daily doses of the SSRI citalopram, and plasma 
adenosine and 5-HT levels were assessed at multiple time-points [234]. 
As expected, plasma levels of 5-HT increased soon after citalopram 
administration, peaking after 12 h, and then gradually decreased [234]. 
This temporal progression remained stable across the 40-day treatment, 
but there was evidence of an increase in the magnitude of the effect, in 
response to prolonged treatment. Interestingly, adenosine levels 
consistently followed the same temporal progression, with a statistically 
significant association being observed [234]. Given this, it is curious 
that the co-administration of adenosine either with the SSRI fluoxetine, 
or the antipsychotic 5-HT type 2A receptor antagonist ketanserin, did 
not lead to a synergistic effect in the FST [231]. On the other hand, a 
synergistic antidepressant effect was observed after co-administration of 
adenosine and the TCA imipramine [227]. Likewise, sub-active – but not 
active – doses of adenosine and the NMDAR antagonists ketamine and 
MK-801, resulted in a synergistic antidepressant-like effect in the FST 
[227]. 
Concluding, evidence supports the notion that increasing adenosine 
levels may have a significantly beneficial impact upon depressive and 
anxious symptomatology. This is fully in line with the therapeutic effects 
reported while targeting adenosine synthesis, catabolism, and transport, 
all of which can lead to a similar increase in adenosine levels. 
3.5. Adenosine receptors 
3.5.1. A1R 
Given the known role of A1R in the regulation of sleep, and the 
relation between altered sleep and MDD, it is interesting to note that in a 
study assessing the association of multiple SNPs in genes coding for el-
ements of the adenosinergic system, no significant effects were found for 
ADORA1 polymorphisms [206]. Furthermore, to the best of our 
knowledge there are no published reports assessing changes in A1R 
levels in the brains of human MDD patients. 
Interestingly, in animal studies, chronic stress exposure has been 
shown to impact hippocampal A1R expression, albeit with contradictory 
results. Specifically, it has been shown that sub-chronic restraint stress 
exposure results in a decrease in hippocampal A1R binding and protein 
levels [235]. Contrastingly, however, a subsequent study using rats 
exposed to either chronic restraint stress or chronic mild stress pro-
tocols, showed the opposite effect, whereby both protocols resulted in an 
increase – rather than a decrease – in hippocampal A1R binding/protein 
levels [236]. 
Pharmacological studies with A1R agonists have largely consistent 
findings. Specifically, it was found that acute administration of the A1R 
agonist CHA led to a decrease in FST immobility times [232]. Likewise, 
another report found weekly CHA administration to have 
antidepressant-like effects in the differential reinforcement of low rate 
72-s (DRL-72 s) schedule assay [237]. Moreover, in addition to 
decreasing FST immobility, acute CCPA administration was also shown 
to lead to a sustained (36 h) reduction of anhedonic-like behavior in the 
SPT [238]. Relatedly, in a recent study, the selective A1R agonist 
MRS5474 was shown to acutely decrease FST immobility times for 
non-stressed mice, as well as to decrease TST immobility in mice 
exposed to a repeated swim stress protocol [239]. Importantly, an early 
study suggested that acute administration of the A1R agonist R-PIA 
mimicked the effects of pre-exposure to inescapable shock on escape 
shuttle performance [226]. However, it must be noted that these authors 
did not control for the possibility that this decrease in performance may 
be attributable to possible hypolocomotion-inducing effects of A1R ag-
onists, rather than a true prodepressant-like effect, despite reporting 
visual evidence of such possible effects. Finally, it must be noted that in 
one study no evidence was found for an antidepressant-like effect of 
acute CHA administration in the FST [213]. 
Interestingly, in addition to having antidepressant-like effects A1R 
agonists also appear to have remarkable potential as drugs to control 
symptoms of anxiety, which often co-occur with MDD. Indeed, an early 
study found that acute administration of the A1R agonist CPA had an 
anxiolytic-like effect in the EPM [240]. Interestingly, these results were 
not observed in a subsequent study [241]. Nonetheless, another study 
found that acute administration of the A1R agonist CCPA had a 
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significant anxiolytic-like effect not just in the EPM, but in the LDBT as 
well, albeit not at all the doses tested, suggesting the possibility that the 
anxiolytic-like effects of this compound may not increase linearly with 
dose [242]. Lastly, ethanol withdrawal is known to have marked 
anxiogenic-like effects in rodents. Interestingly, a report found that 
acute CCPA administration 18 h after ethanol challenge, prevented that 
increase in anxiety, again suggesting an anxiolytic-like effect of A1R 
activation [243]. One important caveat to these results is that, with one 
exception [243], none of the above mentioned studies controlled for the 
possibility that the apparent anxiolytic-like effects of A1R agonists may 
actually derive from locomotor impairing and/or sedating actions of 
these compounds. 
The potential of A1R agonists as add-on drugs to antidepressant drug 
treatment has been explored in a few studies. In this line of research it 
was reported the A1R agonist CHA acutely potentiated the 
antidepressant-like effects of sub-active doses of zinc in the FST [213]. 
However, the same compound was ineffective in potentiating the action 
of the NMDAR antagonist MK-801 in a zebrafish study [202]. 
More recently, attention has been focusing on allosteric modulators 
of A1R, rather than on agonists per se, since allosteric modulators are 
expected to have less side effects and induce less compensatory changes 
in the receptors than those caused by agonists. In this regard, a recent 
study using the novel A1R positive allosteric modulator TRR469 re-
ported acute anxiolytic-like effects in the EPM, LDBT, OFT and MBT, 
that were comparable to those of diazepam [244]. Furthermore, this 
compound did not share the ethanol potentiating properties of diaz-
epam, nor did it induce significant locomotor alterations [244]. Most 
importantly, these effects were associated with increased CCPA binding 
in the hippocampus, amygdala and prefrontal cortex, and were fully 
antagonized by DPCPX pre-treatment, both of which suggest increased 
A1R signaling as the mechanistic underpinning of the effects of TRR469 
[244]. 
In addition to studies with A1R agonists, there has also been 
considerable research focusing the effects of A1R antagonists upon 
depressive- and anxiety-like behaviors. Indeed, acute administration of 
the A1R antagonist DPCPX did not significantly impact FST immobility 
times, but did block the antidepressant-like effects of adenosine [232]. 
These findings have been replicated by multiple subsequent studies, 
with both the TST and FST [213,245,246]. Similarly, other studies found 
that the same compound had no significant impact on DRL-72 s per-
formance after weekly administration [237], nor did it acutely alter 
shuttle-escape performance deficits induced by inescapable shock 
exposure [210], or reserpine-induced FST impairments [247], alto-
gether suggesting no effect of A1R antagonism upon depressive-like 
behaviors. However, a recent study did report acute DPCPX adminis-
tration to induce a significant antidepressant-like effect in both the FST 
and TST [248]. 
Regarding anxiety, Yacoubi et al. found that acute administration of 
the A1R antagonist DPCPX had no effect upon anxiety-like behavior in 
the EPM [241], replicating a similar finding previously obtained by Jain 
et al. with the A1R antagonist CPX [240]. Likewise, acute DPCPX 
administration did not significantly impact ethanol withdrawal-induced 
increases in anxiety in either direction [243]. However a previous study 
reported that the A1R antagonist CPT had a marked anxiogenic-like ef-
fect in both the LDBT and EPM after acute administration [242]. 
Remarkably, a recent study found that chronic exposure to the same 
antagonist resulted in an increase in time spent in the center zone of the 
OFT, suggesting an anxiolytic-like effect of A1R antagonism [249], and 
highlighting that chronic and acute administration of A1R antagonists 
may have quite distinct, if not entirely opposite effects. Such differences 
are expected from a pharmacological point of view, and has been 
documented several times in relation to other A1R-mediated effects of 
the antagonists [56,61,250]. Moreover, different outcomes as a function 
of the tests used are also expected. Indeed, it has been reported that 
while acute administration of the highly selective A1R antagonist 
FR194921 does not significantly impact FST immobility, it does show 
significant anxiolytic like effect in the SIT and the EPM, while also 
reversing scopolamine-induced deficits in passive place avoidance 
[251]. 
In zebrafish, acute DPCPX administration was associated with an 
increased in anxiety-like behavior in the scototaxis test, in addition to 
leading to increased autonomic arousal [252]. 
In addition to their standalone effects, the potential of A1R antago-
nists as adjunct to antidepressant drug treatments has also been 
assessed. It has been recently demonstrated that while DPCPX acutely 
enhances the antidepressant-like effect of sub-active doses of imipra-
mine, escitalopram, and reboxetine [248], it does not have a similar 
interaction with the atypical antidepressants agomelatine and tianeptine 
[246]. Furthermore, another study reported a similar acute 
DPCPX-induced potentiation of the antidepressant-like effects of 
mocloblemide and bupropion in both the FST and TST, and of ven-
lafaxine in the FST alone [245]. On the other hand, acute administration 
of the same compound effectively abolished the antidepressant-like ef-
fect of zinc administration in the mouse FST [213], as well as the 
antidepressant-like effects of the NMDAR antagonist MK-801 in zebra-
fish [202]. 
One of the most puzzling treatments to have demonstrated antide-
pressant efficacy is acute sleep deprivation [253]. In fact, while the 
entire mechanism by which this intervention leads to a reduction in 
depressive symptomatology is not understood, it has been suggested that 
increased adenosine levels leading to an increase in A1R signaling play a 
fundamental role in those effects [43,254]. Indeed, adenosine levels are 
known to increase in response to sleep deprivation [254]. Moreover, it 
has been recently demonstrated that astroglial A1R activation is neces-
sary for the sustained antidepressant-like effects following 12, but not 
72, hours of sleep deprivation, such that these effects are absent in A1R 
KO mice [238,239]. Furthermore, in line with this, there is evidence that 
sleep deprivation leads to a rapid upregulation of A1R, in both humans 
[255] and animals [256–258]. 
Like sleep deprivation, ECT is known to have rapid and pronounced 
antidepressant effects. Moreover, similarly as to what is the case for 
sleep deprivation, ECT has been shown to both increase brain adenosine 
levels [259], as well as to upregulate A1R [212,260]. Furthermore, it has 
been proposed that, insofar NMDAR antagonists are antidepressant, and 
A1R signaling restrains NMDAR activation, this may play a role in the 
antidepressant effects of ECT [161,204]. 
Transcranial direct current stimulation (tDCS) is a non-invasive 
technique of brain stimulation that modulates cortical excitability, and 
has shown some promise in the treatment of MDD [261,262]. While, to 
the best of our knowledge, there is no study determining whether the 
antidepressant-like effects of tDCS are A1R-dependent, it must be noted 
that, in rabbits, tDCS-induced modulation of cortical excitability ap-
pears to rely on A1R activation, as shown by the fact that local appli-
cation of an A1R antagonist prevented the antidepressant-like effects of 
tDCS [263]. 
Similarly to tDCS, deep brain stimulation (DBS) has recently been the 
focus of increasing study as a putative therapy for MDD [264]. It is 
known that the therapeutic effects of DBS in both epilepsy [265] and the 
control of tremors [266] are associated with a marked accumulation of 
adenosine, resulting in increased A1R activation. Thus, it has been 
proposed that this mechanism may also underpin the 
antidepressant-actions of DBS [43,267]. 
The involvement of A1R in MDD has further been probed by genetic 
manipulation studies in animals, the majority of which have focused on 
the KO of A1R. While assessing A1R KO mice in both the FST and TST, no 
significant performance differences were observed relative to WT levels 
[238]. However, a subsequent study found that A1R deletion resulted in 
a significant increase in susceptibility to the deleterious effects of a 
repeated swim stress protocol, behavioral signs of depressive-like 
behavior developed more rapidly and pronouncedly than in WT ani-
mals [239]. Congruently, when tested in the TST and the SPT, A1R KO 
mice presented marked increases in depressive-like behaviors [239]. 
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In addition, a few studies have assessed parameters related to 
anxiety-like behavior. It was found that A1R KO mice have increased 
anxiety-like behavior in the LDBT [268,269], as well as in the OFT, EPM, 
and holeboard tests, while also being significantly more aggressive than 
their WT counterparts in the resident-intruder test [269]. However, a 
subsequent study found A1R KO mice to have almost entirely WT-like 
performance in a battery of tests of anxiety-like behavior, with no dif-
ferences being found either in the LDBT, the OFT, or the O-Maze, and 
only a small increase in anxiety-like behavior observed in the emergence 
test [270]. In addition, at the neurochemical level, it has been reported 
that despite having normal corticosterone responses to acute restraint 
stress, A1R KO mice evidenced abnormally high adrenaline – but not 
noradrenaline (NA) – levels after that stress exposure [271]. Further-
more, after chronic restraint stress, no differences were observed be-
tween WT and A1R KO mice, in any of the aforementioned 
neurochemical parameters [271]. 
Lastly, there have been two studies assessing how increasing A1R 
signaling via its overexpression impact depressive-like behaviors. In line 
with the apparent antidepressant-like effects of A1R agonists, A1R 
overexpression has been shown to result in decreased immobility in both 
the FST and the TST [239]. Furthermore, by selectively turning A1R 
overexpression on or off during repeated swim stress exposure, as well as 
after its end, it was concluded A1R overexpression increased resilience to 
the deleterious effects of stress, but that this resilience only translated 
into reduced TST and FST immobility times, and increased sucrose 
preference, if overexpression was maintained after the end of stress 
exposure [239]. Moreover, increasing A1R overexpression exclusively 
after the end of repeated swim stress, had a significant 
antidepressant-like effect in the above mentioned tests [239]. Curiously, 
in a recent study, the same authors observed that the effects of A1R 
overexpression may be contingent upon the brain regions in which such 
overexpression occurs. Indeed, by comparing the behavioral profiles of 
two strains overexpressing A1R in forebrain neurons, one of which also 
had hippocampal A1R overexpression, a clear difference emerged [272]. 
Specifically, forebrain-only A1R overexpression resulted in a similar 
resilience-promoting and antidepressant-like effect as that previously 
reported, in addition to also resulting in anxiolytic-like effects in the 
EPM, OFT, and LDBT [272]. Contrastingly, while combined forebrain 
and hippocampal A1R overexpression also lead to decreased TST and 
FST immobility, and anxiolytic-like effects in the EPM, OFT, and LDBT, 
without previous stress exposure, it did result in a decrease in resilience 
to the effects of repeated swim stress, and in an increase anhedonic-like 
behavior in the SPT [272]. As such, it seems to be the case that hippo-
campal A1R expression is a key regulator of resilience to the prode-
pressant effects of stress [272]. 
In sum, there is considerable evidence to suggest that A1R play a key 
role in the modulation of depressive and anxious behaviors, and may 
represent an important target for future drug development. Indeed, A1R 
activation was almost entirely reported to produce therapeutic effects, 
and is a likely mechanism for the antidepressant actions of multiple 
existing non-pharmacological treatments. As such, future research 
should focus on better understanding the specific pathways and mech-
anisms underpinning the antidepressant effects of A1R agonists, as well 
as in studying the interaction between this receptor and the A2AR. 
Furthermore, it would be interesting to perform studies that more 
accurately determine the role of A1R in the antidepressant-like effects of 
non-pharmacological interventions such as ECT, tDCS, and DBS. 
3.5.2. A2AR 
Given its widely described role as a regulator of synaptic activity, 
plasticity, and function, it is unsurprising that considerable research has 
been performed aiming at understanding how A2AR is altered in the 
context of MDD, and how manipulations targeting it change depressive 
symptomatology. 
In a small study, MDD patients showed a lower change of platelet 
intracellular Ca2+ in response to different doses of A2AR agonist 
CGS21680, relative to controls [273]. Interestingly, another cross study 
of 1253 individuals from Brazil demonstrated that a TT genotype on the 
rs2298383 SNP in the ADORA2A gene, encoding A2AR, is associated 
with higher resilience to depression, as well as disturbances in sleep and 
attention, which are common symptoms of MDD [274]. Moreover, there 
is evidence for an association between specific ADORA2A poly-
morphisms and panic disorders [275,276]. On the other hand, a study 
focusing on the rs5751876 SNP, in an Asian population that included 
192 subjects with mood disorders patients and 216 control subjects, did 
not observe any correlation between this SNP and MDD [277]. 
In animal studies, sub-chronic restrain stress has been shown to lead 
to an increase in hippocampal A2AR expression [235], whereas exposure 
to a chronic mild stress paradigm was shown to result in the upregula-
tion of striatal A2AR binding [236]. Likewise, in the helpless mouse (HM) 
mouse model of MDD, an increase in hippocampal A2AR density was 
reported [278]. Interestingly, while not an animal model of MDD, it was 
demonstrated that adult rats, submitted to hyperthermia-induced sei-
zures during the neonatal period, displayed a depressive like behavior 
accompanied by an upregulation of cortical A2AR receptors as well as an 
increase in its functionality [279] 
In addition, there is a considerable number of studies reporting the 
impact of pharmacologically targeting A2AR on depressive-like 
symptomatology. 
It has been reported that acute treatment with the A2AR agonist 
DPMA, had no effects on anxiety-like behaviors in mice [240]. 
Furthermore, combined administration of DPMA and the selective A1R 
agonist CPA, prevent the anxiolytic-like effect of the latter [240]. 
Interestingly, CGS21680, another A2AR selective agonist, when acutely 
infused into the nucleus accumbens (NAc) of normal rats, led to an 
identical deficit to that induced by inescapable electric shock stress, in 
the learned helplessness paradigm [280]. Accordingly, a recent study 
demonstrated that acute CGS21680 treatment induced an 
anxiogenic-like effect in normal mice [281]. Curiously, however, these 
results may need to be considered in light of the fact that CGS21680 
administration has been shown to induce reductions in locomotor ac-
tivity, which may underpin its apparent anxiogenic-like effect in the 
EPM [282]. Nonetheless, it should be noted that – despite the apparent 
prodepressant effects of A2AR activation – co-administration of DPMA 
potentiated the antidepressant-like effect of sub-effective doses of zinc in 
the mouse FST [213]. 
Congruently with the above described evidence of an apparent 
prodepressant-like impact of A2AR activation, A2AR antagonists have 
been overwhelmingly shown (but see ref [283]) to exert significant 
antidepressant-like [284], but not anxiolytic-like effects [240,282,283]. 
Indeed, the A2AR antagonists SCH58261, SCH412348, preladenant, 
DMPX and istradefylline (KW6002) have all be shown to acutely reduce 
immobility in the FST and TST [285–288]. However, it must be noted 
that in two of these studies a drug-induced increase in spontaneous lo-
comotor activity was also observed, complicating the interpretation of 
FST and TST results [285,287]. Likewise, a study assessing the antide-
pressant and anxiolytic potential of a series of novel A2AR antagonists 
(KD66, KD167 and KD206), found that while only KD66 appeared to 
have anxiolytic-like effects, all three compounds reduced immobility 
time in the FST and the TST after both acute and chronic treatment 
[289]. Remarkably, this effect was observed, despite spontaneous lo-
comotor activity being unaltered or, in some instances, actually reduced 
by drug treatment [289]. Moreover, chronic KW6002 administration 
improved the inescapable shock-induced escape deficit in a rat learned 
helplessness model, with an effect comparable to that of desipramine 
and fluoxetine [280]. In accordance, it was reported that chronic 
KW6002 treatment had a protective effect over chronic stress-induced 
impairments in behavioral tests of memory, as well as in the FST and 
TST [290]. Similarly, it was observed that acute administration of the 
A2AR antagonists CSC and DMPX could revert the prodepressant effects 
of reserpine and interleukin 1β administration [247,291]. Additionally, 
in OBX rats, 14-day treatment with the A2AR antagonist ZM241385 was 
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decreased immobility in the FST, normalized indexes of anxiety-like 
behavior in the OFT, and reversed anhedonic-like behavior in the SPT 
[233]. 
The capacity of A2AR antagonists to prevent/reverse behavioral al-
terations associated with depressive-like phenotypes has been shown to 
be correlated to additional neurobiological effects. Indeed, concomitant 
SCH58261 administration was shown to prevent early hippocampal 
modifications induced by sub-chronic restraint stress exposure [235]. 
Likewise, chronic KW6002 treatment reversed stress-mediated hippo-
campal deficits in the maternal separation model of MDD [151] 
In addition to their standalone effects, A2AR antagonists have shown 
remarkable promise as putative add-on therapies for existing antide-
pressant compounds. Indeed, A2AR antagonists have been shown to 
acutely potentiate the therapeutic effects of antidepressants spanning 
multiple classes and mechanisms of action, such as fluoxetine [286], 
paroxetine [286], escitalopram [288], imipramine [288], deprenyl 
[286], mocloblemide [245], venlafaxine [245], reboxetine [288], 
bupropion [245], tianeptine [246], and agomelatine [246]. Curiously, 
but in agreement with what has been reported for A2AR agonists, 
co-administration of the A2AR antagonist ZM241385 with zinc, reduced 
the antidepressant-like effects of the latter [213]. 
One interesting niche application of A2AR antagonists is in the mood 
symptoms associated with Parkinson’s disease (PD). Indeed, not only is 
KW6002 already approved for PD pharmacotherapy, as an adjunct to L- 
Dopa/Carbidopa treatment, but there is some tentative evidence that it 
may reduce depressive symptomatology in these patients. Specifically, 
two open label studies with PD patients reported that KW6002 led to 
significant reductions in depressive, anhedonic, and apathy symptom-
atology [292,293] 
Congruently, in a recent study, a newly developed A2AR antagonist 
(compound 33), acutely administered to PD rat models, had significant 
beneficial effect in the FST and TST [294]. Likewise, Lu AA47070A, 
another A2AR antagonist, acutely improved the results of PD rat models, 
in effort-related choice behavior measures, suggesting possible useful-
ness in the motivational symptoms of MDD [295]. Interestingly, these 
effects of A2AR antagonists may be also associated with the modulation 
of DAergic transmission, since A2AR are known to directly interact with 
D2R, decreasing their activity [296–298]. Accordingly, acute adminis-
tration of the A2AR antagonists MSX-3 or KW6002, or of the MSX-2 
prodrug MSX-4, reversed the decreased in effort-related behaviors 
induced by D2R antagonist administration [299–301]. Furthermore, it 
has been suggested that this interaction may also hold functional sig-
nificance for the remaining antidepressant-like effects of A2AR antago-
nists, such as decreased FST/TST immobility [285,286]. 
While the effects of sleep deprivation are thought to be primarily 
mediated by A1R signaling, it is notable that 3− 6 h sleep deprivation 
episodes were found to downregulate olfactory tubercle A2AR [256, 
302]. Thus, considering that A2AR stimulation inhibits A1R activity 
[303] it is compelling to speculate that A2AR downregulation may be 
involved with the antidepressant effects of sleep deprivation mediated 
by A1R. 
Work concerning genetic manipulation of A2AR expression has 
largely confirmed the pharmacological findings. Specifically, in line 
with the notion that A2AR activation has a prodepressant-like impact, it 
has been reported that adult rats overexpressing human A2AR in neurons 
present with a depressive-like phenotype, as evidenced by increased FST 
immobility, decreased sucrose preference in the SPT, in addition to 
presenting hyperlocomotion [304]. Conversely, and again in agreement 
with A2AR antagonist studies, A2AR knockout mice show increased 
decreased immobility in the FST/TST [305]. Furthermore, these animals 
show increased resilience to the deleterious effects of chronic stress 
exposure at the behavioral, neurochemical and synaptic plasticity levels 
[290]. 
In summary, there is considerable evidence to support the notion 
that A2AR plays an important role in the pathophysiology and treatment 
of MDD. Indeed, evidence suggests that increased A2AR signaling – 
which can be triggered by stress exposure – has largely prodepressant 
effects, which can be prevented or reversed by treatment with A2AR 
antagonists. Importantly, it should be noted that insofar A2AR antago-
nists are known to increase locomotor activity, data derived from tests 
vulnerable to being biased by locomotor changes (e.g., FST, TST) have to 
be interpreted cautiously. Nonetheless, congruent A2AR antagonist- 
induced antidepressant-like effects were found in tests not reliant on 
locomotor measures, such as the SPT, and these treatments also 
appeared to have beneficial effects on the motivational symptoms of 
MDD as well. As such, future studies should focus on determining the 
specific mechanisms underpinning the antidepressant actions of A2AR 
antagonists (e.g., interactions with A1R and/or D2R), as well as on 
exploring the role played by this receptor in the pathophysiology of 
MDD. 
3.5.2.1. Caffeine. Caffeine is by far the most widely consumed psy-
choactive substance in the world, being used for its positive effects on 
mood and alertness. Importantly, while caffeine is a non-selective 
adenosine receptor antagonist, it is commonly thought that the major-
ity of its therapeutic and neuroprotective effects primarily derive from 
A2AR antagonism. 
Human epidemiological data has consistently shown that caffeine 
intake is associated with a decreased risk of MDD diagnosis. A 10-year 
prospective study of over 50,000 US women free from MDD at base-
line, found those individuals consuming 2–3 cups of coffee a day were at 
a decreased risk of being diagnosed with MDD, in relation to those 
consuming 1 or less cups a day [306]. Similarly, a subsequent 
meta-analysis of observational studies found evidence for a 
dose-dependent protective effect of coffee – but not tea – over depressive 
symptoms [307]. Largely in agreement, another meta-analysis found a 
similar dose-dependent effect, hereby MDD risk decrease by approxi-
mately 8% for each daily cup consumed [308]. Furthermore, these au-
thors found that the beneficial effects of caffeine did not follow a linear 
progression, but were greater at 68− 509 mg/day [308]. 
In line with this, multiple animal studies have reported that acute 
administration of caffeine induces a significant antidepressant-like ef-
fect, as evidenced by decreased immobility time in both the FST and the 
TST [309–311] (but see reference [225]), and by improved escape 
behavior in the escape shuttle paradigm [312]. In fact, this was the case 
even after animals had been previously exposed to an chronic unpre-
dictable stress protocol, as shown by an acute dose-dependent caffei-
ne-induced decrease in FST immobility time [313]. Similarly, a single 
administration of caffeine was enough to rescue reserpine-induced in-
creases in FST immobility time, suggesting an antidepressant effect 
[247]. However, it must be noted that while this latter study did not 
control for the possible locomotor effects of caffeine [247], in the former 
work a significant increase in spontaneous locomotor activity was 
observed after caffeine treatment [313], which may have led to the ef-
fects observed in the FST. 
Like acute treatment, chronic caffeine treatment seems to have a 
significant antidepressant effect, which may result from the fact that 
A2AR, unlike A1R, are less prone to adapt while chronically manipulated. 
Indeed, it has been reported that 2-week daily caffeine treatment, 
starting after a 4-week chronic unpredictable stress protocol, had a 
protective effect [314]. Specifically, these authors observed that, despite 
caffeine inducing anxiogenic-like effects in control animals, in 
stress-exposed subjects it had anxiolytic- and antidepressant-like effects, 
in the EPM, as well as the FST and the SPT, respectively [314]. More-
over, not only did caffeine treatment prevent the stress-induced decrease 
in hippocampal 5-HT and DA levels, it actually raised them above 
control-levels [314]. 
Furthermore, in addition to treating already present depressive-like 
deficits – and in line with the human data reported above – there is 
evidence to support the notion that chronic caffeine treatment may have 
a prophylactic effect against the deleterious effects of stress. Indeed, a 
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recent study demonstrated that 3-week caffeine exposure prior to the 
onset of a chronic unpredictable stress protocol, largely prevented the 
development of increased anxiety- and depressive-like behaviors, of 
cognitive impairments, and of several MDD-associated neurobiological 
alterations, such as increased corticosterone levels, astrogliosis, and loss 
of synaptic markers [290]. In line with this, a recent study reported that 
chronic (14 day) pre-treatment with caffeine protected mice against the 
prodepressant and anxiogenic effects of a CSDS protocol, as assessed in 
the OFT, SIT and SPT [315]. Intriguingly, however, similar effects were 
not observed if chronic treatment started at the same time, or after the 
end of, CSDS exposure [315]. Likewise, acute treatment, irrespectively 
of whether performed before the onset of CSDS or after its end, had no 
protective effect [315]. Curiously, these authors also found that in 
non-CSDS-exposed animals, chronic caffeine treatment had no impact 
on baseline FST, TST or OFT performance [315]. Similarly, in a study 
using HM, while chronic caffeine intake reversed memory deficits and 
the loss of hippocampal synaptic markers – possibly due to antagonism 
of upregulated hippocampal A2AR – it had no effect on depressive- or 
anxiety-like behaviors [278]. 
On the other hand, it has been reported that simultaneous chronic 
daily exposure to restraint stress and caffeine, resulted in a male-specific 
decreases and increases in plasma corticosterone, and hippocampal DNA 
damage [316]. Furthermore, these authors found that caffeine – both 
with and without concomitant restraint stress exposure – also induced 
male-specific increases in anxiety-like behavior, in the EPM [316]. 
Finally, one consistent finding relates to the synergistic effect of 
caffeine with conventional antidepressant treatments. Indeed, it has 
been consistently demonstrated that a sub-active dose of caffeine is 
capable of significantly increasing the antidepressant-like effects of 
conventional antidepressant compounds belonging to multiple classes, 
including SSRIs [311], TCAs [311], 5-HT and NA reuptake inhibitors 
[310,317], NA and DA reuptake inhibitors [310,317], reversible 
monoamine oxidase A inhibitors [317], NAergic and specific 5-HTergic 
antidepressants [318], melatonin receptor agonists [318], NMDAR an-
tagonists [309]. Remarkably, this potential as an effective add-on 
treatment to antidepressant drugs has also been demonstrated in 
human MDD patients, taking the SSRI escitalopram [319]. However, it 
must be noted that while caffeine may potentiate the effects of antide-
pressant compounds, caffeine withdrawal may have the opposite result. 
Indeed, a recent study with rats exposed to caffeine for 14-days found 
that, whereas caffeine-maintained animals showed an increased 
antidepressant-like response to sub-effective SSRI treatment, in animals 
undergoing caffeine withdrawal the opposite was observed [311]. 
Altogether, data derived from caffeine studies not only reinforces the 
potential of A2AR antagonism as a highly viable strategy for the treat-
ment of MDD, but also highlights a highly interesting potential appli-
cation of caffeine: that of a magnifier of the effects conventional 
antidepressant drugs. Indeed, it would be extremely interest to analyze 
existing data from antidepressant drug trials, and determine what – if 
any – is the impact of caffeine use upon the success of drug therapy. 
Furthermore, it would be highly relevant to study the specific mecha-
nisms which underpin this apparent caffeine-induced potentiation of 
antidepressant drug effects. 
3.5.3. A2BR 
To the best of our knowledge there are no published reports assessing 
if/how A2BR are altered either in MDD patients, or animal models of 
MDD, nor tying ADORA2B polymorphisms to MDD. 
Congruently with this lack of data, and despite the apparent role 
played by A2BR in neuroinflammatory activity [157,320], and the 
relationship between neuroinflammation and depressive-like states [22, 
23], very few reports have actually assessed how A2BR-targetted ma-
nipulations impact emotional behavior. Specifically, a 2015 study using 
reserpinized rats found that acute treatment with the selective A2BR 
antagonist alloxazine had no effect upon the reserpine-induced increases 
in immobility time in the FST [247]. Curiously, a study with A2BR 
knockout mice, found them to present a slightly altered anxiety-like 
behavior profile: while A2BR-KO mice did not present changes in 
anxiety-like behavior, they did spend more time than WT littermates in 
the center zone of the EPM [321]. Furthermore, these authors reported 
altered Y-Maze behavior in A2BR-KO mice, which they interpreted as 
indicating an increased exploratory drive [321]. Finally, it has been 
reported that, while fluoxetine does not directly target A2BR, it leads to 
an increase in BDNF levels – which is known to be associated to 
antidepressant-like effects – through a mechanism relying on 
ATP-derived adenosine activating astroglial A2BR [322]. 
Concluding, there is not enough data to confidently postulate a role 
for A2BR in the pathophysiology and treatment of MDD. However, in our 
opinion, this topic should be investigated in future research. 
3.5.4. A3R 
There appear to be no published reports assessing A3R alterations in 
MDD patients, or animal models. Likewise, we found no reports relating 
ADORA3 polymorphisms to MDD. It should be noted, however, that 
specific ADORA3 polymorphisms have been associated to altered 5-HT 
transporter (SERT) function [323]. While these alterations have been 
exclusively associated to autism spectrum disorders, it is possible – given 
the role of 5-HT dysfunction in the pathophysiology of MDD, and of 
5-HT reuptake inhibition in its treatment – that these ADORA3 poly-
morphisms may hold relevance for MDD. 
Indeed, despite the fact that A3R has been shown to directly interact 
and regulate SERT function [45,323,324], to the best of our knowledge, 
the effects of A3R receptor manipulation were only assessed in a single 
study. Specifically, behavioral phenotyping of A3R-KO mice revealed no 
differences from WT littermates regarding anxiety-like behavior, 
assessed in the EPM and the LDBT [325]. On the other hand, in the FST 
and the TST, A3R-KO mice spent significantly more time immobile than 
WT mice, despite evidencing increased locomotor activity, suggesting an 
increase in depression-like behavior [325]. Finally, when these animals 
were exposed to a fear conditioning paradigm, no differences were 
observed vis a vis WT controls [325]. 
Similarly to what is the case with A2BR, there is not nearly enough 
evidence to confidently assert the relevance of A3R as a target for the 
treatment of MDD, nor as a player in the pathophysiology of the disor-
der. However, even more than A2BR, A3R may prove to be a highly 
interesting and fruitful object of MDD research, given its relation with 
SERT, and is clearly deserving of further study. 
4. Concluding remarks 
In this work, we aimed at reviewing the available evidence impli-
cating adenosine in the pathophysiology of MDD, as well as the evidence 
regarding the consequences of manipulating this neuromodulatory sys-
tem on depressive and anxious symptoms (summarized in Table 3). 
Altogether, we believe there is enough evidence to confidently assert 
that MDD significantly impacts the expression and functioning of the 
adenosinergic system, with data being most robust regarding A1R and 
A2AR. Moreover, in our review of the data, we consistently found that 
increasing adenosine levels – be it through pharmacological or non- 
pharmacological means – leads to reliable antidepressant and anxio-
lytic effects. Furthermore, it seems to be the case that these beneficial 
effects of adenosine, are primarily related to A1R activation – which was 
consistently shown to have desirable antidepressant and anxiolytic 
properties – but not A2AR activation. Indeed, the functional opposition 
between A1R and A2AR clearly manifests in the reviewed data: whereas 
A1R agonism is antidepressant, A2AR agonism is not. Conversely, 
whereas A1R antagonism does not induce desirable effects, A2AR 
antagonism consistently evokes antidepressant-like effects. As such, it 
would be interesting to determine whether this functional opposition 
can be better exploited for therapeutic means, by – for example – 
combining selective A1R agonists and A2AR antagonists. 
In fact, this is only one of many possible future avenues of research 
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that we have observed, many of which we have evidenced across the 
present work. Indeed, despite the apparent promise of the adenosinergic 
system as a target for the development of novel antidepressant treat-
ments, there are still significant gaps in the already existing literature, as 
well as important unexplored avenues of research. 
For one, there is a clear dearth of studies using models of MDD – that 
is manipulations purporting to replicate the pathophysiological features 
of MDD, such as the chronic mild stress model, rather than just a specific 
endophenotype of it (e.g., FST) [326]. These models are key for a better 
understanding of how the adenosinergic system itself is first impacted by 
depressive-like deficits. But more importantly than that, by actually 
inducing MDD-like neurobiological changes in the animals, these 
models allow for a more realistic – and, therefore, more likely to have 
translational success – test of the therapeutic potential of novel adeno-
sinergic compounds. 
Likewise, another important gap pertains to the considerable lack of 
work concerning the A2BR and A3R, as well as the enzymes and trans-
porters that constitute the adenosinergic system. In fact, given the role of 
dysfunctional 5-HT signaling and neuroinflammation in the patho-
physiology of MDD [15,22,23], the A3R seems like a prime target for 
investigation as both a stand-alone and a possible add-on treatment. 
On the other hand, we believe that better exploring the possibility 
that drugs preferentially targeting different A1R and A2AR populations 
(e.g., pre- vs. post-synaptic) would also be highly interesting. In fact, it 
has been shown that the effects of certain compounds are primarily 
attributable to the activation of receptors located in specific cellular 
localizations, rather than to the activation of all receptors [49,327]. 
Similarly, more hypothesis-driven, mechanistic and focused work 
regarding the specific cellular populations and signaling pathways 
involved in the effects of adenosinergic drugs – by themselves or in 
combination with other antidepressant compounds – would be highly 
desirable. Indeed, one of the most consistently reported findings here 
reviewed, pertained to the synergistic effect of caffeine and antide-
pressants [328]. While this combination might not be a true break-
through in terms of therapeutic effectiveness, it does represent a 
possibly easy, safe, and affordable way of maximizing the therapeutic 
benefit of these compounds while also reducing their side-effects by – for 
example – allowing the use of lower doses. 
Lastly, the role played by adenosine receptor heteromers in the 
pathophysiology and treatment of MDD remains a wholly unexplored 
field. While this is not entirely surprising, considering how relatively 
recent the evidence of functional heteromers is, it is the most significant 
gap in the literature and one that might hold considerable interest. This 
is all the more surprising when considering that adenosine receptors are 
known to form functional heteromers not just with one another (e.g., 
A1R-A2AR [329]), but also with receptors from other systems deeply 
impacted by MDD [49,330–333]. Moreover, these heteromers have been 
shown to be involved in the regulation of important processes, whose 
dysfunction may be key in the development and/or treatment of this 
disorder [334]. Critically, the payoff from such research may come in 
the form not just of a novel and more profound understanding of the 
pathophysiology of MDD, but also in the form of novel primary or 
add-on treatments to either increase antidepressant efficacy, or decrease 
undesirable effects. Indeed, this has already been shown to some extent, 
as demonstrated by the fact that the deleterious effects of CB1R agonists 
can be mitigated through interaction with A2AR-CB1R heteromers [49]. 
Thus, concluding, we believe that there is ample evidence to support 
the notion that adenosine and the adenosinergic system is an important 
player in the pathophysiology of MDD, and represents a prime target for 
the development of novel drugs for the treatment of this disorder. 
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[143] S. Ferré, C. Quiroz, A.S. Woods, R. Cunha, P. Popoli, F. Ciruela, C. Lluis, 
R. Franco, K. Azdad, S.N. Schiffmann, An update on adenosine A2A-dopamine D2 
receptor interactions: implications for the function of G protein-coupled 
receptors, Curr. Pharm. Des. 14 (2008) 1468–1474. 
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[297] S. Ferré, M. Díaz-Ríos, J.D. Salamone, R.D. Prediger, New developments on the 
adenosine mechanisms of the central effects of caffeine and their implications for 
neuropsychiatric disorders, J. Caffeine Adenosine Res. 8 (2018) 121–131, https:// 
doi.org/10.1089/caff.2018.0017. 
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J. Rodrigues, P.M. Canas, A. Köfalvi, R.A. Cunha, D. Rial, Adenosine A 2b 
receptors control A 1 receptor-mediated inhibition of synaptic transmission in the 
mouse hippocampus, Eur. J. Neurosci. 41 (2015) 878–888, https://doi.org/ 
10.1111/ejn.12851. 
[322] M. Kinoshita, Y. Hirayama, K. Fujishita, K. Shibata, Y. Shinozaki, E. Shigetomi, 
A. Takeda, H.P.N. Le, H. Hayashi, M. Hiasa, Y. Moriyama, K. Ikenaka, K. 
F. Tanaka, S. Koizumi, Anti-depressant fluoxetine reveals its therapeutic effect via 
astrocytes, EBioMedicine 32 (2018) 72–83, https://doi.org/10.1016/j. 
ebiom.2018.05.036. 
[323] N.G. Campbell, C.-B. Zhu, K.M. Lindler, B.L. Yaspan, E. Kistner-Griffin, NIH ARRA 
Consortium, W.A. Hewlett, C.G. Tate, R.D. Blakely, J.S. Sutcliffe, Rare coding 
variants of the adenosine A3 receptor are increased in autism: on the trail of the 
serotonin transporter regulome, Mol. Autism 4 (2013) 28, https://doi.org/ 
10.1186/2040-2392-4-28. 
[324] K.J. Miller, B.J. Hoffman, Adenosine A3 receptors regulate serotonin transport via 
nitric oxide and cGMP, J. Biol. Chem. 269 (1994) 27351–27356. 
[325] I.M. Fedorova, M.A. Jacobson, A. Basile, K.A. Jacobson, Behavioral 
characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic 
neurodegeneration, Cell. Mol. Neurobiol. (2003) 17. 
[326] M.F. Ferreira, L. Castanheira, A.M. Sebastiao, D. Telles-Correia, Depression 
assessment in clinical trials and pre-clinical tests: a critical review, Curr. Top. 
Med. Chem. 18 (2018), https://doi.org/10.2174/ 
1568026618666181115095920. 
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